Emergex Vaccines Holding Limited

Emergex Vaccines is a company pioneering a new approach to vaccine development and manufacturing using cutting-edge technologies to produce novel synthetic vaccines intended to fight against viral and bacterial infectious diseases. The company develops synthetic non-biological components that prime immune cells to destroy pathogen-infected cells for diseases that include dengue fever, zika, ebola and pandemic flu as well as serious intra-cellular bacterial infections.

Emergex aims to offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical-grade international vaccine repository to act as a first line of defense in the case of existing and newly emerging infectious disease outbreaks.

The company based in Abingdon, Oxfordshire, was founded in 2016 by Thomas Rademacher (CEO) and Storme Moore-Thornicroft (Executive Director & COO). Rademacher is Professor Emeritus of molecular medicine at the University College London Medical School and has founded and led several successful biotechnology companies. Moore-Thornicroft previously founded Midiatech Pharma PLC, she specializes in entity incorporation, corporate and business strategy.

The company has raised a total of $12.3M in 2 rounds of funding. In May 2018 a $1.3M grant from Innovate UK, part of UK Research and Innovation (UKRI) the government's national funding agency investing in science and research. In January 2020, Emergex raised $11M in Series A funding led by Vickers Venture Partners. Dr. Finian Tan, chairman of Vickers Venture Partners, has joined Emergex’s board of directors.

The company has raised a total of $12.3M in 2 rounds of funding. In May 2018 a $1.3M grant from Innovate UKInnovate UK, part of UK Research and Innovation (UKRI) the government's national funding agency investing in science and research. In January 2020, Emergex raised $11M in Series A funding led by Vickers Venture Partners. Dr. Finian Tan, chairman of Vickers Venture Partners, has joined Emergex’s board of directors.

The company based in Abingdon, Oxfordshire, was founded in 2016 by Thomas RademacherThomas Rademacher (CEO) and Storme Moore-Thornicroft (Executive Director & COO). Rademacher is Professor Emeritus of molecular medicine at the University College London Medical School and has founded and led several successful biotechnology companies. Moore-Thornicroft previously founded Midiatech Pharma PLC, she specializes in entity incorporation, corporate and business strategy.

The company based in Abingdon, OxfordshireOxfordshire, was founded in 2016 by Thomas Rademacher (CEO) and Storme Moore-Thornicroft (Executive Director & COO). Rademacher is Professor Emeritus of molecular medicine at the University College London Medical School and has founded and led several successful biotechnology companies. Moore-Thornicroft previously founded Midiatech Pharma PLC, she specializes in entity incorporation, corporate and business strategy.